BAGUERAC Cervical Disc Prosthesis
Spineart USA, Inc. · Decision date Sep 22, 2026
What did the FDA approve?
Spineart USA, Inc. submitted a post-approval study protocol for the BAGUERA C Cervical Disc Prosthesis under supplement S002 to PMA P250042. The FDA database records the decision as APPR and lists the supplement type as Normal 180 Day Track No User Fee, with the supplement reason given as Postapproval Study Protocol.
The statement indicates the protocol was submitted to comply with conditions of approval in the approval order for P250042. The record does not include the protocol contents, study endpoints, enrollment targets, or any safety or effectiveness findings. The submission of a protocol is distinct from evidence that the device is safe or effective.
FDA approval order statement
requested approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250042
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Orthopedic
- Decision date
- Sep 22, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250042/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Spineart USA, Inc.
- Product code
- MJO
- Decision code
- APPR
- Decision date
- Sep 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, intervertebral disc.
- Applicant
- Spineart USA, Inc.
- Product code
- MJO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250042. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250042 · Original PMA
BAGUERAC Cervical Disc Prosthesis
P250042/S002 received
Application receipt date recorded by FDA.
P250042/S002 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P250042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Spineart USA, Inc. | PMA approval | Aug 10, 2026 | FDA |
Explore the linked device profile
Other records with product code MJO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Synergy DiscP250028/S003 | Synergy Spine Solutions, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
prodisc C NovaP070001/S031 | Centinel Spine, LLC | PMA supplement | Sep 9, 2026 | FDA |
Synergy DiscP250028 | Synergy Spine Solutions, Inc. | PMA approval | Feb 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Spineart USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 23332 Mill Creek Dr., Suite 150, Laguna Hills, CA, 92653
Sources and methodology
- Original FDA record: P250042/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


